Compare Citius Pharmaceuticals Inc (CTXR) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs GoPro Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while GoPro Inc trades at $0.62 (market cap $120.42M). The key difference: GoPro Inc is far larger — about 6.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GPRO | |
|---|---|---|
Market Cap | $18.73M | $120.42M |
Sector | Health | Technology |
52-Week High | $1.82 | $2.88 |
52-Week Low | $0.48 | $0.62 |
Enterprise Value | $14.95M | $168.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
GoPro (GPRO) trades at $0.73, down 0.38% on the day, reflecting persistent financial distress. The stock is in a bearish technical trend, with negative earnings surprises in recent quarters and a net income margin of -20.7% for 2025. Revenue has declined from $1.1B in 2022 to $652M in 2025, while the company is actively pursuing strategic alternatives, including a potential sale, as announced in May 2026.
The outlook is highly speculative, hinging on the outcome of the strategic review. A successful sale could unlock value, but fundamental weaknesses—including cash burn, negative equity, and competitive pressures—pose significant risks. Analyst sentiment is mixed, with a majority Hold rating, indicating caution amid the binary event-driven thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
